Numerous new active pharmaceutical ingredient (API) manufacturing plants and specialized chemical synthesis blocks are continuously being established across India, driven by government production-linked incentive (PLI) schemes designed to boost domestic manufacturing self-reliance. Major Indian pharmaceutical corporations regularly invest in greenfield facilities across industrial hubs in Gujarat, Telangana, and Andhra Pradesh.